nimodipine has been researched along with Hyponatremia in 1 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Hyponatremia: Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Large-vessel cerebral vasospasm has been challenged as the sole causal mechanism; new hypotheses now focus on the early brain injury, microcirculatory dysfunction, impaired autoregulation, and spreading depolarization." | 2.53 | Management of delayed cerebral ischemia after subarachnoid hemorrhage. ( Francoeur, CL; Mayer, SA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Francoeur, CL | 1 |
| Mayer, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inter- and Intra-Observer Variability in Transcranial Doppler (TCD) Technique in Neurocritical Care Patients[NCT04583163] | 12 participants (Anticipated) | Observational | 2020-09-22 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nimodipine and Hyponatremia
| Article | Year |
|---|---|
Management of delayed cerebral ischemia after subarachnoid hemorrhage.
Topics: Brain Ischemia; Calcium Channel Blockers; Disease Management; Humans; Hyponatremia; Hypotension; Hyp | 2016 |